This resolution matters because it provides official recognition from a branch of the U.S. government for a historical medical tragedy that continues to affect millions. For those who are "DES Daughters," "DES Sons," or mothers who took the drug, this acknowledgment can validate their struggles and bring much-needed attention to a public health issue that has had generational impacts. By supporting a "DES Awareness Week," it could help inform individuals who might not realize their health problems are linked to DES exposure, prompting them to seek appropriate medical guidance.

Furthermore, the resolution's call to restore funding for the DES Follow-Up Study underscores the ongoing need for research into the drug's long-term and often complex effects. The urging of an FDA apology is significant as it seeks accountability from a federal agency whose initial approval of DES led to widespread suffering. While a resolution doesn't create new laws or directly allocate funds, it serves as a powerful statement of congressional intent, which can influence future policy decisions, public health initiatives, and agency actions regarding this important historical issue.